GGrantIndex
Sort

46,585 grants matching heart failure

A Digital Twin for Designing Bladder Treatment informed by Bladder Outlet Obstruction Mechanobiology (BOOM)

$646,286
Anne Marie Robertson · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DK

Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys

$646,234
Angus W Thomson · University Of Pittsburgh At Pittsburgh · U01 · FY2011 · AI

Organizational resilience: A novel strategy for improving ICU outcomes

$646,230
Deena Kelly Costa · Yale University · R01 · FY2023 · HL

Modulation of Protective RAS-GPCR Pathways in Aortic Disease

$646,151
Sadashiva S. Karnik · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · HL

Advancing RAS and RASopathy Therapies

$646,143
Marielle Yohe · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Research and Development of Effective Therapies for Patients with Rare Tumors

$646,140
Brigitte Widemann · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA

Genetically Informed Smoking Cessation Trial

$646,105
Li-Shiun Chen · Washington University · R01 · FY2018 · DA

Evaluation of the effectiveness of Ajjmuurur Baamḷe DSMES in the RMI

$645,979
Sheldon Riklon · Univ Of Arkansas For Med Scis · R01 · FY2023 · DK

BNP and Neuroimmune Characteristics of CHF & Depression

$645,946
Paul J Mills · University Of California, San Diego · R01 · FY2013 · HL

A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children

$645,902
Michele Kong · University Of Alabama At Birmingham · R01 · FY2024 · HD

Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells

$645,796
Ken Nakamura · J. David Gladstone Institutes · R01 · FY2021 · AG

Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells

$645,796
Ken Nakamura · J. David Gladstone Institutes · R01 · FY2022 · AG

Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells

$645,796
Ken Nakamura · J. David Gladstone Institutes · R01 · FY2023 · AG

Thromboregulatory strategies to prolong xenograft survival.

$645,765
Simon C Robson · Beth Israel Deaconess Medical Center · U01 · FY2009 · AI

Disruption of the Cardiac-Coronary Axis as a Mechanism of HFpEF

$645,671
Liya Yin · University Of Arizona · R01 · FY2024 · HL

Metabolic Function in Pulmonary Vascular Disease

$645,613
John Hughes Newman · Vanderbilt University Medical Center · P01 · FY2018 · HL

Patient Navigators: Secondary Prevention in Underserved Coronary Disease Patients

$645,607
Diane M Becker · Johns Hopkins University · R01 · FY2008 · NR

Implementing Effective Smoking Cessation Pharmacotherapy for Hospitalized Smokers with Cardiopulmonary Disease

$645,590
Quinn Russell Pack · Baystate Medical Center, Inc. · R01 · FY2025 · HL

Ischemia/Reperfusion injury and Myocardial edema

$645,489
Michael Simons · Yale University · R01 · FY2024 · HL

Programming amylin secretion to slow brain aging - an animal model

$645,472
Florin Despa · University Of Kentucky · R01 · FY2021 · AG

Physiology of Unloading VA ECMO Trial

$645,394
Joseph Edward Tonna · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL

Advanced Glycation End-Products in Human Myocardium

$645,290
Martin M Lewinter · University Of Vermont & St Agric College · R01 · FY2009 · HL

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP).

$645,285
Carolyn Harmon Still · Case Western Reserve University · R01 · FY2025 · NR

The state of energy in the right ventricle of patients with pulmonary arterial hypertension

$645,281
Arash Kheradvar · University Of California-Irvine · R01 · FY2023 · HL

Volumetric Echocardiographic Particle Image Velocimetry for Grading the Severity of Mitral Valve Regurgitation

$645,279
Arash Kheradvar · University Of California-Irvine · R01 · FY2023 · HL